Ms. Evelyn Harrison, M.B.A., has been the Chief Clinical Operations Officer Ophthotech Corporation since January 11th 2016. Ms. Harrison served as the Chief Operating Officer of Ophthotech Corporation since August 2007 until January 11th 2016. Ms. Harrison has more than 19 years of management and clinical research experience. Her professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann LaRoche, where she served as Director of Clinical Operations responsible for the development and implementation of strategic programs for Roche's Oncology franchise. From 2000 to 2006, Ms. Harrison was with Eyetech Pharmaceuticals, where she held the management positions of Vice-President and Senior Vice-President of Clinical Research and Development and played a key role in the development and approval of Macugen® for Age-Related Macular Degeneration. Ms. Harrison continued to play a major role in the transition when Eyetech merged with OSI Pharmaceuticals to become OSI-Eyetech. She has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone-marrow transplantation, organ transplantation, oncology, and virology. Her contributions led to the approval of new drugs such as Zenapax® and Xeloda® in the U.S. and Europe. Ms. Harrison holds a B.A. degree in Biology from Hofstra University and the M.B.A. from Manhattan College. Ms. Evelyn Harrison, M.B.A., has been the Chief Clinical Operations Officer Ophthotech Corporation since January 11th 2016. Ms. Harrison served as the Chief Operating Officer of Ophthotech Corporation since August 2007 until January 11th 2016. Ms. Harrison has more than 19 years of management and clinical research experience. Her professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann LaRoche, where she served as Director of Clinical Operations responsible for the development and implementation of strategic programs for Roche's Oncology franchise. From 2000 to 2006, Ms. Harrison was with Eyetech Pharmaceuticals, where she held the management positions of Vice-President and Senior Vice-President of Clinical Research and Development and played a key role in the development and approval of Macugen® for Age-Related Macular Degeneration. Ms. Harrison continued to play a major role in the transition when Eyetech merged with OSI Pharmaceuticals to become OSI-Eyetech. She has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone-marrow transplantation, organ transplantation, oncology, and virology. Her contributions led to the approval of new drugs such as Zenapax® and Xeloda® in the U.S. and Europe. Ms. Harrison holds a B.A. degree in Biology from Hofstra University and the M.B.A. from Manhattan College.

Eye Diseases and Disorders